Parent

"JEWISH NOBEL" AWARDED TO PFIZER CEO ALBERT BOURLA

Retrieved on: 
Wednesday, January 19, 2022 - 8:33pm
Entrepreneurship, Genesis Prize, Research, University, Laureate, Vaccine, Memory, Prize, White House, Time (magazine), Stockholm Environment Institute US Center, COVID-19, Refugee, List of lifetime achievement awards, Johnson & Johnson, Science, Genesis, Microbiology, Nazism, Sputnik 1, Social justice, History of the Jews in Greece, CEO, Government, Foundation, Survivor, Committee, Leadership, The Holocaust, History, TIME, Parent, Supreme Court of the United States, Epidemiology, Family, Federation, Chief executive officer, Supreme court, RNA transfection, Vaccine Research Center, Online gambling, Pharmaceutical industry, Jewellery, Pfizer, Jews, New England Patriots

JERUSALEM, Jan. 19, 2022 /PRNewswire/ -- Today, The Genesis Prize Foundation announced Dr. Albert Bourla, Chairman and CEO of Pfizer, as the 2022 Genesis Prize Laureate. Dr. Bourla received the largest number of votes in a recently concluded global campaign, during which 200,000 people in 71 countries voted online. The choice of the voters was unanimously endorsed by the nine judges on the Genesis Prize Selection Committee.

Key Points: 
  • Dr. Bourla received the largest number of votes in a recently concluded global campaign, during which 200,000 people in 71 countries voted online.
  • The Committee commended Dr. Bourla for his leadership, determination, and especially for his willingness to assume great risks.
  • The President of Israel Isaac Herzog will present the Genesis Prize to Dr. Bourla at a ceremony in Jerusalem planned for June 29.
  • "I am delighted to welcome Dr. Albert Bourla to the distinguished family of Genesis Prize Laureates," said Co-Founder and Chairman of The Genesis Prize Foundation Stan Polovets.

"JEWISH NOBEL" AWARDED TO PFIZER CEO ALBERT BOURLA

Retrieved on: 
Wednesday, January 19, 2022 - 8:06pm
Entrepreneurship, Genesis Prize, Research, University, Laureate, Vaccine, Memory, Prize, White House, Time (magazine), Stockholm Environment Institute US Center, COVID-19, Refugee, List of lifetime achievement awards, Johnson & Johnson, Science, Genesis, Microbiology, Nazism, Sputnik 1, Social justice, History of the Jews in Greece, CEO, Government, Foundation, Survivor, Committee, Leadership, The Holocaust, History, TIME, Parent, Multimedia, Supreme Court of the United States, Epidemiology, Family, Federation, Chief executive officer, Supreme court, RNA transfection, Vaccine Research Center, Online gambling, Pharmaceutical industry, Jewellery, Pfizer, Jews, New England Patriots

JERUSALEM, Jan. 19, 2022 /PRNewswire/ -- Today, The Genesis Prize Foundation announced Dr. Albert Bourla, Chairman and CEO of Pfizer, as the 2022 Genesis Prize Laureate. Dr. Bourla received the largest number of votes in a recently concluded global campaign, during which 200,000 people in 71 countries voted online. The choice of the voters was unanimously endorsed by the nine judges on the Genesis Prize Selection Committee.

Key Points: 
  • Dr. Bourla received the largest number of votes in a recently concluded global campaign, during which 200,000 people in 71 countries voted online.
  • The Committee commended Dr. Bourla for his leadership, determination, and especially for his willingness to assume great risks.
  • The President of Israel Isaac Herzog will present the Genesis Prize to Dr. Bourla at a ceremony in Jerusalem planned for June 29.
  • "I am delighted to welcome Dr. Albert Bourla to the distinguished family of Genesis Prize Laureates," said Co-Founder and Chairman of The Genesis Prize Foundation Stan Polovets.

Lex A. Mitchell, MD, is recognized by Continental Who's Who

Retrieved on: 
Wednesday, January 19, 2022 - 7:55pm
Arkansas School for Mathematics, Sciences, and the Arts, HI, American Board of Radiology, Patient, American Board of Commissioners for Foreign Missions, Kaiser Permanente, PET, University, ABR, Injury, Medical imaging, Arkansas Tech University, Army of the United States, General medical services, Lucile Packard Children's Hospital, Medicare Physician Group Practice (PGP) Demonstration, Society, Magnetic resonance imaging, Continental, X-ray, Parent, Tripler Army Medical Center, CT, Education, Hospital, MD, Madigan Army Medical Center, Multimedia, Lieutenant colonel, Medicine, Radiological Society of North America, Brain, Mitchell, Mobile phone, Chemistry, Radiology

HONOLULU, Jan. 19, 2022 /PRNewswire/ -- Lex A. Mitchell, MD, is being recognized by Continental Who's Who as a Distinguished Radiologist for his many years of outstanding service in the field of Radiology.

Key Points: 
  • HONOLULU, Jan. 19, 2022 /PRNewswire/ -- Lex A. Mitchell, MD, is being recognized by Continental Who's Who as a Distinguished Radiologist for his many years of outstanding service in the field of Radiology.
  • As a highly trained radiologist with 16 years of experience, Dr. Mitchell treats patients at Kaiser Permanente Moanalua Medical Center in Honolulu, HI.
  • Dr. Mitchell has been in the position for two years, during which he has aided countless patients.
  • As a physician with Hawaii Permanente Medical Group, Dr. Mitchell is part of Hawaii's largest multispecialty group practice.

Vera Whole Health, Inc. Announces Commencement of the Tender Offer for All Outstanding Shares of Castlight Health, Inc.

Retrieved on: 
Wednesday, January 19, 2022 - 7:30pm
Carbon, Transfer, MAKE, Tripura Merger Agreement, Financial condition report, SEC, Common stock, WELL, NYSE, EACH, U.S. Securities and Exchange Commission, Agreement, Compte rendu, LLC, CLST, COMMON, Risk, Delaware General Corporation Law, Clayton, Dubilier & Rice, DGCL, TIME, Company, Multimedia, Hart–Scott–Rodino Antitrust Improvements Act, Letter, Annual report, Telephone, Forward-looking statement, Health, CD, AND, PARTIES, Schedule, Plan, Result, IR, Conversation, Acquisition, Money transmitter, Dubilier, R, THE, Population, Fortune 500, Wall Street, View, Communication, AS, Security (finance), CD&R, Analysis, Terminology, Cryptocurrency, Castlight Health, Asset purchase agreement, Parent

The tender offer is being made pursuant to the merger agreement (the "Merger Agreement") executed on January 4, 2022 and announced by Vera and Castlight on January 5, 2022.

Key Points: 
  • The tender offer is being made pursuant to the merger agreement (the "Merger Agreement") executed on January 4, 2022 and announced by Vera and Castlight on January 5, 2022.
  • Additionally, Castlight is filing a solicitation/recommendation statement on Schedule 14D-9 that will include the recommendation of Castlight's board of directors that Castlight's stockholders tender their shares in the tender offer.
  • The tender offer for the outstanding shares of common stock of Castlight has commenced.
  • Vera has filed a tender offer statement on Schedule TO with the SEC, and Castlight will file a solicitation/recommendation statement on Schedule 14D-9 with respect to the offer.

The Launch of Raising Addy - A place to learn, share ideas and support parents of special needs children

Retrieved on: 
Wednesday, January 19, 2022 - 6:30pm
Parent, Child, Addy, Intel, Residential care

CHICAGO, Jan. 19, 2022 /PRNewswire-PRWeb/ --Today is the official launch of Raising Addy, a place to learn, share ideas and support parents of special needs children.

Key Points: 
  • CHICAGO, Jan. 19, 2022 /PRNewswire-PRWeb/ --Today is the official launch of Raising Addy, a place to learn, share ideas and support parents of special needs children.
  • It allows parents/caregivers to ask questions, share ideas and learn from other parents/caregivers facing similar unknowns and battles.
  • The Raising Addy platform also has useful resources, therapists and products utilized by special needs parents that have proven to be extremely helpful.
  • Raising Addy, is a place parents/caregivers can come to learn, share, listen and obtain helpful information in raising a special needs child.

Mobile Application Market to Value US$ 717 Bn by 2030; Notes TMR Study

Retrieved on: 
Wednesday, January 19, 2022 - 5:30pm
Online, CAGR, Cognizant, Mobile web, Aarogya Setu, Algorithm, Nokia, National Data Sharing and Accessibility Policy – Government of India, COVID-19, US, Population, Growth, Digital, Mental health, Hewlett Packard Enterprise, School, App Store (iOS/iPadOS), Parent, IBM, Coursera, Prevalence, Lists of countries and territories, Smartphone, TMR, Apple Inc., Mobile phone, Medtech

Transparency Market Research (TMR) has conducted a detailed analysis on various factors associated with the growth of the mobile application market .

Key Points: 
  • Transparency Market Research (TMR) has conducted a detailed analysis on various factors associated with the growth of the mobile application market .
  • The TMR analysts project the global market for mobile application to expand at a CAGR of 20.2% during the forecast period of 2020-2030.
  • The global mobile application market stood at US$ 113.8 Bn in 2020 and is prognosticated to reach US$ 717 Bn by 2030.
  • Novel startups are emerging in the e-learning apps space, which will propel the growth prospects of the mobile application market.

Mobile Application Market to Value US$ 717 Bn by 2030; Notes TMR Study

Retrieved on: 
Wednesday, January 19, 2022 - 5:30pm
Online, CAGR, Cognizant, Mobile web, Aarogya Setu, Nokia, Algorithm, National Data Sharing and Accessibility Policy – Government of India, COVID-19, US, Adoption, Population, Growth, Digital, Mental health, Hewlett Packard Enterprise, School, App Store (iOS/iPadOS), Parent, IBM, Coursera, Prevalence, Lists of countries and territories, Smartphone, TMR, Apple Inc., Mobile phone, Medtech

ALBANY, N.Y., Jan. 19, 2022 /PRNewswire/ -- Mobile Internet penetration has increased significantly over the years. With high smartphone adoption and extensive mobile Internet penetration, the demand for mobile applications has scaled phenomenally. Based on these aspects, the mobile application market will observe substantial growth opportunities.

Key Points: 
  • Transparency Market Research (TMR) has conducted a detailed analysis on various factors associated with the growth of the mobile application market .
  • The TMR analysts project the global market for mobile application to expand at a CAGR of 20.2% during the forecast period of 2020-2030.
  • The global mobile application market stood at US$ 113.8 Bn in 2020 and is prognosticated to reach US$ 717 Bn by 2030.
  • Novel startups are emerging in the e-learning apps space, which will propel the growth prospects of the mobile application market.

FGA Finds That States That Require Youth Work Permits Decrease Their Workforce and Creates Barries To Work For Teens

Retrieved on: 
Wednesday, January 19, 2022 - 5:20pm
Ageing, Fair Labor Standards Act of 1938, Workforce, Health, Safety, FGA, Parent, Foundation for Government Accountability, Child, Public policy, American Dream, Student, Solution, Foundation, Unemployment, Birth control

NAPLES, Fla., Jan. 19, 2022 /PRNewswire-PRWeb/ -- Yesterday, the Foundation for Government Accountability (FGA) identified a barrier to work that many states have created by using youth work permits to determine a teenager's eligibility to participate in the workforce.

Key Points: 
  • NAPLES, Fla., Jan. 19, 2022 /PRNewswire-PRWeb/ -- Yesterday, the Foundation for Government Accountability (FGA) identified a barrier to work that many states have created by using youth work permits to determine a teenager's eligibility to participate in the workforce.
  • In comparison, state-created youth work permits are certifications issued by school administrators that grant teenagers permission to work.
  • States that delay the hiring process for teenage workers with youth work permits may be unintentionally cutting off a critical source of their workforce.
  • "State lawmakers should eliminate youth work permits to end the influence given to school administrators and restore the decision-making rights to students and their parents."

Eisai's Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study

Retrieved on: 
Wednesday, January 19, 2022 - 1:06am
People, Biomarker, Research, Washington University School of Medicine, Dementia, Tau, Seed, University College London, DIAD, Population, Safety, Domination, BAN2401, Disease, Solution, Parent, Tauopathy, Risk, Alzheimer's disease, Amyloid, Brain, Rapunzel's Tangled Adventure (season 2), Neurology, Amnesia, Amyloid beta, Partnership, Pharmaceutical industry, Medical imaging, Vaccine, Eisai

The study will assess the effect of Eisai's investigational anti-microtubule binding region (MTBR) tau antibody E2814, in dominantly inherited Alzheimer's disease (DIAD).

Key Points: 
  • The study will assess the effect of Eisai's investigational anti-microtubule binding region (MTBR) tau antibody E2814, in dominantly inherited Alzheimer's disease (DIAD).
  • In March 2021, the DIAN-TU selected E2814, which was created from a research collaboration between Eisai and University College London, as the first investigational medicine among anti-tau drugs for the Tau NexGen study.
  • With increasing evidence from clinical studies showing that targeting amyloid can reduce biomarkers of AD, the Tau NexGen clinical trial leaders selected Eisai's investigational anti-Abeta protofibril antibody lecanemab (BAN2401) as the background anti-amyloid therapy, and the study design was amended in November 2021.
  • In the Tau NexGen study, symptomatic participants will be administered anti-amyloid beta (Abeta) protofibril antibody lecanemab for six months before being randomly assigned to also receive the anti-tau drug or a placebo.

Aldo Esterhuizen, PhD, HCLD (ABB), Joins Ovation Fertility as Lab Director

Retrieved on: 
Wednesday, January 19, 2022 - 2:00pm
Research, Patient, Gynaecology, Publication, Bavishi Fertility Institute, IVF, Department of Obstetrics and Gynecology (Massachusetts General Hospital), Andrology, South African Medical Association, Obstetrics, GLOBE, Embryology, Egg, Department, University of Pretoria, Tygerberg, ABB, Parent, Infertility, Dental Council, Fertility, Association, Stellenbosch University, Pregnancy, Physician, Family, Compliance, Laboratory, Genetic testing, American Association, University, Endocrinology, Medicine, Science, Bioanalysis, Ovation

Nashville, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Ovation Fertility is pleased to announce that Aldo Esterhuizen, Ph.D., HCLD (ABB) , has joined the company as a lab director.

Key Points: 
  • Nashville, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Ovation Fertility is pleased to announce that Aldo Esterhuizen, Ph.D., HCLD (ABB) , has joined the company as a lab director.
  • In this role, she will oversee all IVF, embryology and andrology operations at the Ovation Fertility Nashville IVF lab, while ensuring lab safety and compliance.
  • Its rare to find a lab director with the breadth and depth of experience that Dr. Esterhuizen brings to the table, says Conor Beardsley, Ovation president.
  • Ovation also helps IVF labs across America improve their quality and performance with expert off-site lab direction and consultation.